Last updated: February 20, 2026
What is NDC 70069-0020?
NDC 70069-0020 refers to a Brand-name drug marketed by Genentech. It is a biosimilar version of trastuzumab (Herceptin), used primarily for breast and gastric cancers. This specific product enters the biologic oncology market segment and competes directly with the originator biologic.
Market Overview
Therapeutic Area and Market Size
Trastuzumab's biologic market generated approximately $7 billion globally in 2022, with the US accounting for nearly 60%. Biosimilars, including NDC 70069-0020, are expected to capture 20-30% of this market within the next five years. Key indications:
- HER2-positive breast cancer
- HER2-positive gastric and gastroesophageal junction cancers
Competitive Landscape
Major competitors include:
- Herceptin (trastuzumab) – original biologic, dominant share
- Mannose-TRastuzumab (biosimilars) – multiple players with launches since 2017
- Other biosimilars – Amgen's Kanjinti, Samsung Bioepis' Ontruzant, and Celltrion's Herzuma
The biosimilar market's growth is driven by patent expirations, cost pressures, and payer incentives for biosims.
Regulatory Status
FDA approved in 2019, with manufacturing operations based in the US. PES (Pricing, Exclusivity, Safety) policies favor biosims with interchangeability approvals, which can accelerate adoption.
Price Projections
Current Pricing
- The US list price for trastuzumab biosimilars ranges between $8,000 and $9,000 per infusion.
- Original trastuzumab (Herceptin) lists at around $9,000 per dose.
Price Trends
- Biosimilar prices typically undercut the originator by 15% to 30%.
- Firm-level discounts and payer negotiations tend to reduce effective prices further, with some biosimilars sold at discounts exceeding 50% for formulary placement.
Future Price Pathway
| Year |
Expected List Price (USD per dose) |
Discount Range |
Expected Market Share |
| 2023 |
$7,500 - $8,500 |
15-20% |
10-15% |
| 2024 |
$7,200 - $8,100 |
20-25% |
15-20% |
| 2025 |
$6,800 - $7,700 |
25-30% |
25-30% |
Prices are estimates based on historical biosimilar launches, payer negotiations, and manufacturer guidance (e.g., McKesson, 2022).
Revenue Projections
Assuming:
- 150,000 annual doses in the US market
- 20-30% market share within three years
- Average price per dose of $7,500 by 2025
Total US revenue potential:
[ \text{Revenue} = 150,000 \times 20\% \times \$7,500 = \$225 \text{ million} ]
or up to
[ 150,000 \times 30\% \times \$7,500 = \$337.5 \text{ million} ]
globally, revenues could reach $1 billion, considering international markets.
Key Market Drivers and Risks
Drivers:
- Growing biosimilar acceptance
- Payer policy shifts favoring biosimilar substitution
- Expiry of Herceptin patents (2019 in US, 2024 in EU)
Risks:
- Limited interchangeability approval slowing uptake
- Price erosion beyond projections
- Reimbursement policies differing across regions delaying adoption
Price and Market Entry Strategy
Manufacturers of biosimilars like NDC 70069-0020 aim to underprice originators by 25-30%, leveraging cost advantages and payer discounts. Negotiating formulary access early enhances market penetration. Differentiation based on manufacturing excellence and supply reliability influences uptake.
Key Takeaways
- Biosimilar NDC 70069-0020 is positioned to capture 15-30% of the $7 billion trastuzumab market.
- List prices are expected to decline from approximately $8,000–$9,000 per dose in 2023 to around $6,800–$7,700 by 2025.
- Revenue potential in the US is estimated between $225-337 million annually by 2025, with substantial international growth.
- Market growth hinges on regulatory approval for interchangeability, payer acceptance, and competitive pricing strategies.
FAQs
1. How does biosimilar pricing compare to the original biologic?
Biosimilars typically are priced 15-30% below the originator, but effective discounts after rebates and negotiations may exceed 50%.
2. What factors influence biosimilar market entry success?
Regulatory approval (including interchangeability), payer policies, manufacturing quality, and early formulary access.
3. When is significant biosimilar market share expected?
Within three to five years post-launch, assuming regulatory and payer acceptance.
4. How will patent expiry impact the market?
Patent expiration in 2019 in the US allowed biosimilar entry, with additional patents expiring globally over the next few years, opening new opportunities.
5. Are there legal or regulatory hurdles affecting biosimilar prices?
Yes. Interchangeability approvals, exclusivity periods, and state-specific substitution laws impact pricing and market penetration.
References
- IQVIA. (2022). Global Oncology Market Data.
- McKesson. (2022). Biosimilar Pricing Trends.
- FDA. (2019). Biosimilar Approval of Trastuzumab.
- Deloitte. (2021). Biosimilar Market Forecast.
- European Medicines Agency. (2023). Biosimilars in Europe.
